American Healthcare REIT vs Americold Realty Trust
AHR and COLD side by side, both in miscellaneous investing. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AHR and COLD compare
American Healthcare REIT is the larger company, worth 2.8 times as much as Americold Realty Trust ($12.9B against $4.6B).
On earnings, Americold Realty Trust is cheaper: it trades at 19.5× trailing earnings, against 121× for American Healthcare REIT.
American Healthcare REIT grew revenue faster over the last twelve months (21.5% versus 1.3% for Americold Realty Trust).
Americold Realty Trust keeps more of each dollar of sales as profit, with a net margin of 9.0% compared with 3.6% at American Healthcare REIT.
Both pay dividends: American Healthcare REIT yields 1.7% and Americold Realty Trust 5.7%.
Americold Realty Trust scores higher on the StockData Score (12 against 11 for American Healthcare REIT), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AHR | COLD |
|---|---|---|
| Size and price | ||
| Market cap | $12.9B | $4.6B |
| Share price | $59.23 | $16.18 |
| Change, 1 year | 20.0% | 43.3% |
| Change, 5 years | – | −49.7% |
| Beta (5Y) | 0.45 | 0.72 |
| Employees | 121 | 13K |
| StockData Score | ||
| Total score | 11 | 12 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 5 (better) | 2 |
| Performance score | 3 | 3 |
| Health score | 2 (better) | 0 |
| Dividend score | 1 | 3 (better) |
| Valuation | ||
| P/E | 121× | 19.5× (better) |
| P/S | 4.8× | 1.7× (better) |
| P/B | 2.3× | 1.5× (better) |
| EV/EBITDA | 15.4× | 5.8× (better) |
| FCF yield | – | −2.9% |
| Fair value | $23.64 | $28.77 |
| Margin of safety | −151% | 43.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 21.5% (better) | 1.3% |
| Revenue growth, 5Y average | 16.2% (better) | 5.5% |
| Net income growth (TTM) | 253% | – |
| EPS growth (TTM) | 250% | – |
| EPS growth, 5Y average | 53.1% | – |
| Profitability | ||
| Gross margin | 22.1% | 32.2% (better) |
| Operating margin | 20.2% (better) | 15.1% |
| Net margin | 3.6% | 9.0% (better) |
| FCF margin | – | −5.1% |
| Return on equity | 2.3% | 7.9% (better) |
| Return on invested capital | 13.7% (better) | 13.2% |
| Financial health | ||
| Interest coverage | 7.2× (better) | 2.4× |
| Altman Z-score | 4.24 (better) | 0.67 |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 1.7% | 5.7% (better) |
| Payout ratio | 193% | 111% |
| Years of dividend growth | 0 | – |
| Dividend growth, 5Y average | 3.1% | – |
| Buyback yield | −23.0% | – |
| Shareholder yield | −21.4% | 5.7% (better) |
| Ownership | ||
| Held by institutions | 103% | 109% |
| Held by insiders | 0.63% | 10.4% |
| Insider net buying, 12 months | −$4.6M | −$25.4K (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 15.5% | 11.4% |
Go deeper
- AHR stock overview
- AHR income statement
- AHR valuation and score
- COLD stock overview
- COLD income statement
- COLD valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.